{"id":199881,"date":"2025-06-20T12:46:10","date_gmt":"2025-06-20T12:46:10","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/199881\/"},"modified":"2025-06-20T12:46:10","modified_gmt":"2025-06-20T12:46:10","slug":"gopath-diagnostics-announces-launch-of-diabetesnow-a-genetic-test-panel-designed-to-clarify-diabetes-diagnosis","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/199881\/","title":{"rendered":"GoPath Diagnostics Announces Launch of DiabetesNow: A Genetic Test Panel Designed to Clarify Diabetes Diagnosis"},"content":{"rendered":"<p>            <a data-fancybox=\"gallery\" href=\"https:\/\/www.manilatimes.net\/manilatimes\/uploads\/images\/2025\/06\/20\/660162.jpg\" data-caption=\"\" target=\"_blank\" rel=\"noopener\"><\/p>\n<p>                        <img decoding=\"async\" class=\"lazy\" src=\"https:\/\/www.manilatimes.net\/manilatimes\/uploads\/images\/2025\/06\/20\/660162.jpg\" alt=\"No Image\" data-alt- data-default- width=\"100%\" height=\"100%\" onerror=\"this.src=\" https:=\"\"\/><\/p>\n<p>            <\/a><\/p>\n<p>GoPath Diagnostics, a leading provider of molecular and digital pathology services, today announced the launch of DiabetesNow, a comprehensive genetic test developed to support the diagnosis, classification, and management of diabetes<\/p>\n<p>Buffalo Grove, IL, June 20, 2025 (GLOBE NEWSWIRE) &#8212; <strong>A More Complete Genetic View of Diabetes<\/strong><\/p>\n<p>DiabetesNow combines testing for 16 genes associated with monogenic forms of diabetes-including MODY, neonatal, syndromic, and mitochondrial types-with polygenic risk scores (PRS) for type 1 and type 2 diabetes across diverse ancestries. It also includes GenProb-T1D, a model that estimates the likelihood of type 1 diabetes based on genetic and clinical inputs.<\/p>\n<p>Additionally, the panel detects key SNPs linked to both type 1 and type 2 diabetes and helps clarify uncertain cases by identifying inherited gene variants that may be shared among family members-supporting early detection in at-risk relatives. Importantly, DiabetesNow can help distinguish MODY from type 1 and type 2 diabetes in patients with unclear diagnoses, which is essential for guiding appropriate therapy and informing medication choices.<\/p>\n<p><strong>Designed for Early-Onset and Atypical Cases<\/strong><\/p>\n<p>Get the latest news<br \/>\n                <br class=\"br-line\"\/><br \/>\n                delivered to your inbox<\/p>\n<p>Sign up for The Manila Times newsletters<\/p>\n<p>            By signing up with an email address, I acknowledge that I have read and agree to the <a href=\"https:\/\/www.manilatimes.net\/terms-of-service\" title=\"Terms of Service\" target=\"_blank\" rel=\"noopener\">Terms of Service<\/a> and <a href=\"https:\/\/www.manilatimes.net\/privacy-policy\" title=\"Privacy Policy\" target=\"_blank\" rel=\"noopener\">Privacy Policy<\/a>.<\/p>\n<p>DiabetesNow is especially valuable for patients diagnosed at an early age, those with mild or non-progressive hyperglycemia, or those whose clinical presentation doesn&#8217;t fit typical type 1 or type 2 patterns. The panel&#8217;s 16 genes were selected based on recommendations from the Monogenic Diabetes Expert Panel (MDEP) and current clinical literature.<\/p>\n<p>&#8220;DiabetesNow brings together the most relevant genetic markers in a single panel, helping providers better distinguish between complex diabetes presentations and offer more tailored care,\u201d said Dr. Jim Lu, CEO and Medical Director of GoPath Diagnostics.<\/p>\n<p><strong>Backed by Data, Built for Clinical Practice<\/strong><\/p>\n<p>GoPath&#8217;s internal database of previously tested patients enables robust variant interpretation and clinically actionable reporting. Each test report includes monogenic variant analysis, PRS percentile rank by ancestry, and a GenProb-T1D score-delivering comprehensive insight in one streamlined report.<\/p>\n<p>DiabetesNow reflects the latest advancements in diabetes genetics, incorporating findings from Billings et al., The Journal of Clinical Endocrinology &amp; Metabolism (2023) and aligning with the 2024 American Diabetes Association (ADA) Standards of Care.<\/p>\n<p><strong>About GoPath Diagnostics<\/strong><\/p>\n<p>GoPath Diagnostics specializes in molecular, genetic, anatomic pathology, hematopathology, cytology, and digital pathology services. With advanced technologies and a dedicated team of laboratory professionals, GoPath delivers accurate, timely, and actionable results to support patient care and empower providers with expanded diagnostic insight. Learn more at: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LpnMGAJdBM2SFxkVDW2eXSCzRcjMEZu-JutatU6EE_E46-iVpdDmSVxnHruHBGj6Z8t-madjNiiuoHnCVNjsKQ==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"gopathdx.com\">gopathdx.com<\/a><\/p>\n<p>CONTACT: Name: Edgar Castellanos<\/p>\n<p>Email: <a href=\"https:\/\/www.manilatimes.net\/cdn-cgi\/l\/email-protection\" class=\"__cf_email__\" data-cfemail=\"c4a1a7a5b7b0a1a8a8a5aaabb784a3abb4a5b0aca0bceaa7aba9\" target=\"_blank\" rel=\"noopener\">[email\u00a0protected]<\/a><\/p>\n<p>Job Title: Director of Marketing &amp; Product Development<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"'https:\/\/ml.globenewswire.com\/media\/YTZhMTcxYTItN2NiYy00MzM4LWEwODctMzhjZTRmYjM3OTg1LTUwMDE0ODQwMC0yMDI1LTA2LTIwLWVu\/tiny\/GoPath-Diagnostics.png'\" referrerpolicy=\"'no-referrer-when-downgrade'\"\/><\/p>\n","protected":false},"excerpt":{"rendered":"GoPath Diagnostics, a leading provider of molecular and digital pathology services, today announced the launch of DiabetesNow, a&hellip;\n","protected":false},"author":2,"featured_media":199882,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3846],"tags":[14040,33049,80857,80856,967,80854,7371,80853,3899,267,80852,1325,3577,80855,70,32504,6093,16,15],"class_list":{"0":"post-199881","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-genetics","8":"tag-a","9":"tag-announces","10":"tag-clarify","11":"tag-designed","12":"tag-diabetes","13":"tag-diabetesnow","14":"tag-diagnosis","15":"tag-diagnostics","16":"tag-genetic","17":"tag-genetics","18":"tag-gopath","19":"tag-launch","20":"tag-of","21":"tag-panel","22":"tag-science","23":"tag-test","24":"tag-to","25":"tag-uk","26":"tag-united-kingdom"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/114715767414617750","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/199881","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=199881"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/199881\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/199882"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=199881"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=199881"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=199881"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}